Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 140,039 | 168,006 | 199,552 | 83,170 | 102,515 |
| Receivables | 2,910 | 3,379 | 1,845 | 3,984 | 2,414 |
| TOTAL | $149,634 | $177,378 | $203,568 | $89,916 | $109,060 |
| Non-Current Assets | |||||
| PPE Net | 2,845 | 2,727 | 2,601 | 2,703 | 2,745 |
| Intangibles | 3,844 | 3,725 | 3,868 | 3,900 | 3,948 |
| Other Non-Current Assets | 306 | 285 | 297 | 296 | 296 |
| TOTAL | $6,995 | $6,736 | $6,765 | $6,899 | $6,989 |
| Total Assets | $156,629 | $184,115 | $210,333 | $96,815 | $116,048 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 17,088 | 18,643 | 14,472 | 12,718 | 11,410 |
| TOTAL | $17,527 | $19,116 | $14,893 | $13,784 | $13,358 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 103 | 100 | 104 | 935 | 1,788 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $17,527 | $19,116 | $14,893 | $13,784 | $13,358 |
| Shareholders' Equity | |||||
| Common Shares | 4,801 | 4,652 | 4,818 | 3,778 | 3,820 |
| Retained earnings | 114,436 | 143,601 | 176,231 | 66,792 | 88,083 |
| Other shareholders' equity | 19,865 | 16,746 | 14,391 | 12,462 | 10,788 |
| TOTAL | $139,102 | $164,999 | $195,440 | $83,032 | $102,691 |
| Total Liabilities And Equity | $156,629 | $184,115 | $210,333 | $96,815 | $116,048 |